Related Experiment Video

Updated: Sep 19, 2026

Involving Individuals with Developmental Language Disorder and Their Parents/Carers in Research Priority Setting
06:16

Involving Individuals with Developmental Language Disorder and Their Parents/Carers in Research Priority Setting

Published on: June 6, 2020

Correction: Designing integrated early-phase protocols to reduce substantial modifications, including considerations

R Schultz-Heienbrok1, S Baumann2, R Böhm3,4

  • 1Charité Research Organisation GmbH, Berlin, Germany.

Frontiers in Pharmacology
|September 17, 2026
PubMed

Abstract:

[This corrects the article DOI: 10.3389/fphar.2025.1699906.].

Keywords:
clinical trialscomplex trial designfirst-in-humanintegrated protocolsinvestigational medicinal productsubstantial modification

More Related Videos

A Structured Rehabilitation Protocol for Improved Multifunctional Prosthetic Control: A Case Study
06:58

A Structured Rehabilitation Protocol for Improved Multifunctional Prosthetic Control: A Case Study

Published on: November 6, 2015

Related Experiment Videos

Last Updated: Sep 19, 2026

Involving Individuals with Developmental Language Disorder and Their Parents/Carers in Research Priority Setting
06:16

Involving Individuals with Developmental Language Disorder and Their Parents/Carers in Research Priority Setting

Published on: June 6, 2020

A Structured Rehabilitation Protocol for Improved Multifunctional Prosthetic Control: A Case Study
06:58

A Structured Rehabilitation Protocol for Improved Multifunctional Prosthetic Control: A Case Study

Published on: November 6, 2015

Related Concept Videos

Preclinical Development: Overview01:28

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
Methods of Documentation VI: Case Management Model01:15

Methods of Documentation VI: Case Management Model

The case management model is a multidisciplinary approach that involves healthcare professionals from diverse disciplines, such as physicians, nurses, therapists, social workers, and pharmacists, working collaboratively to address the various needs of patients. Each healthcare professional brings unique expertise and perspectives, contributing to a more comprehensive understanding of the patient's condition and tailoring treatment plans accordingly.
For example, a patient with a chronic illness...

Articles linked to this work by shared authors, journal, and citation graph.

The Oncology Research Information Exchange Network (ORIEN) - Building a Real-World Collaborative, Patient-driven Infrastructure for Discovery Research and Precision Oncology.

Research square·2026

Designing integrated early-phase protocols to reduce substantial modifications, including considerations for patient cohorts - a multi-stakeholder consensus view for a practical approach in Germany.

Frontiers in pharmacology·2026

The Global Bioequivalence Harmonisation Initiative (GBHI): Report of the sixth international EUFEPS/PQRI conference.

European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences·2025

Heterogeneity in Dental Tissue-Derived MSCs Revealed by Single-Cell RNA-seq.

Journal of dental research·2024

[Proposal for participation in intensive care and emergency medicine studies for patients unable to give informed consent (Cologne Model)].

Medizinische Klinik, Intensivmedizin und Notfallmedizin·2023

The Global Bioequivalence Harmonisation Initiative (GBHI): Report of the fifth international EUFEPS/AAPS conference.

European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences·2023

Correction: Apocynum venetum leaf extract alleviated doxorubicin-induced cardiotoxicity by regulating organic acid metabolism in gut microbiota.

Frontiers in pharmacology·2026

Risk of neoplasms with semaglutide in patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials.

Frontiers in pharmacology·2026

Role of the cGAS-STING signaling pathway in diabetes mellitus and its complications: from mechanisms to therapeutics.

Frontiers in pharmacology·2026

Exposure-response relationship of sintilimab in advanced gastric cancer: insights from time-dependent pharmacokinetics and biomarker integration for precision immunotherapy.

Frontiers in pharmacology·2026

Pharmaco-multiomics in major depressive disorder: a narrative review and proposed translational framework for difficult-to-treat and treatment-resistant depression.

Frontiers in pharmacology·2026

Protein kinase C-λ drives third-degree burn-induced muscle wasting via STAT3-dependent catabolic pathways.

Frontiers in pharmacology·2026

A case of tic improvement following tipepidine administration in a boy with Tourette syndrome comorbid with attention-deficit/hyperactivity disorder and autism spectrum disorder.

PCN reports : psychiatry and clinical neurosciences·2026

Subcutaneous MG1113 in severe hemophilia A and B: phase 1b study for safety, pharmacokinetics, and pharmacodynamics.

Research and practice in thrombosis and haemostasis·2026

Efficacy and safety of different TPO-RAs combined with cyclosporine in the treatment of NSAA.

Therapeutic advances in hematology·2026

Mesenchymal Stem Cell-Derived Extracellular Vesicles Ameliorate NaIO3-Induced Dry AMD by Delivering miR-486-3p to Inhibit Lipocalin-2-Mediated Ferroptosis.

MedComm·2026

Effectiveness and safety of telitacicept in refractory ocular myasthenia gravis: a retrospective, real-world study.

Frontiers in immunology·2026

Agomelatine as augmentation therapy with second-generation antipsychotics for negative symptoms of schizophrenia: An open-label randomised clinical trial and electroencephalogram-derived model for treatment response prediction.

General psychiatry·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us